Development of Hyperactive Sleeping Beauty Transposon Vectors by Mutational Analysis
Overview
Pharmacology
Affiliations
The Sleeping Beauty (SB) transposable element is a promising vector for transgenesis in vertebrates and is being developed as a novel, nonviral system for gene therapeutic purposes. A mutagenesis approach was undertaken to improve various aspects of the transposon, including safety and overall efficiency of gene transfer in human cells. Deletional analysis of transposon sequences within first-generation SB vectors showed that the inverted repeats of the element are necessary and sufficient to mediate high-efficiency transposition. We constructed a "sandwich" transposon, in which the DNA to be mobilized is flanked by two complete SB elements arranged in an inverted orientation. The sandwich element has superior ability to transpose >10-kb transgenes, thereby extending the cloning capacity of SB-based vectors. We derived hyperactive versions of the SB transposase by single-amino-acid substitutions. These mutations act synergistically and result in an almost fourfold enhancement of activity compared to the wild-type transposase. When combined with hyperactive transposons and transiently overexpressed HMGB1, a cellular cofactor of SB transposition, hyperactive transposases elevate transposition by almost an order of magnitude compared to the first-generation transposon system. The improved vector system should prove useful for efficient gene transfer in vertebrates.
Ranjan V, Leighton G, Yan C, Arango M, Lustig J, Corona R Nucleic Acids Res. 2024; 53(2.
PMID: 39657726 PMC: 11754664. DOI: 10.1093/nar/gkae1188.
A novel hyperactive variant of the transposase facilitates non-viral genome engineering.
Ochmann M, Miskey C, Botezatu L, Sandoval-Villegas N, Diem T, Ivics Z Mol Ther Nucleic Acids. 2024; 35(4):102381.
PMID: 39654540 PMC: 11626015. DOI: 10.1016/j.omtn.2024.102381.
Assessing and engineering the IscB-ωRNA system for programmed genome editing.
Yan H, Tan X, Zou S, Sun Y, Ke A, Tang W Nat Chem Biol. 2024; 20(12):1617-1628.
PMID: 38977787 DOI: 10.1038/s41589-024-01669-3.
Diaby M, Wu H, Gao B, Shi S, Wang B, Wang S Adv Sci (Weinh). 2024; 11(29):e2400969.
PMID: 38774947 PMC: 11304231. DOI: 10.1002/advs.202400969.
Antibiotic-Free Gene Vectors: A 25-Year Journey to Clinical Trials.
Marie C, Scherman D Genes (Basel). 2024; 15(3).
PMID: 38540320 PMC: 10970329. DOI: 10.3390/genes15030261.